Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013050 · ClinicalTrials.gov registry record · Phase 2
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
A Phase 2 study, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT02013050 is a Phase 2 study that has completed, run by Soligenix. The registered enrollment target is 111 participants.
The verdict
NCT02013050, a Phase 2 study, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
Interventions
- DRUG Placebo
- DRUG SGX942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013050
The ClinicalTrials.gov registry entry for NCT02013050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02013050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013050 about?
NCT02013050 is a clinical study titled "A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer". To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
What is the current status of trial NCT02013050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2013-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02013050?
The interventions under investigation include: Placebo (DRUG), SGX942 (DRUG).
Who is sponsoring clinical trial NCT02013050?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.